REGNHealthcare · BiotechnologyThe 27 Wall Street analysts covering Regeneron Pharmaceuticals, Inc. hold a median 12-month price target of $857 — +15.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 8 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Regeneron Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (39): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (4): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on REGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +15.9% from it.
Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Morgan Stanley | Maintains | Equal-Weight | $758 → $779 |
| 7 Oct 2026 | Truist Securities | Maintains | Buy | $772 → $780 |
| 6 Oct 2026 | JP Morgan | Maintains | Overweight | $900 → $950 |
| 1 Oct 2026 | Argus Research | Upgrade | Buy | $850 |
| 1 Oct 2026 | Jefferies | Maintains | Buy | $870 → $930 |
| 29 Sept 2026 | RBC Capital | Reiterates | Sector Perform | $737 |
| 10 Sept 2026 | HSBC | Maintains | Buy | — |
| 10 Sept 2026 | HSBC | Maintains | Buy | $800 → $920 |
| 17 Aug 2026 | Leerink Partners | Maintains | Market Perform | $641 → $824 |
| 17 Aug 2026 | Leerink Partners | Maintains | Market Perform | — |
| 3 Aug 2026 | Citigroup | Maintains | Neutral | $700 → $740 |
| 3 Aug 2026 | Citigroup | Maintains | Neutral | — |
| 3 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 3 Aug 2026 | Guggenheim | Maintains | Buy | $1,000 → $1,030 |
| 31 July 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 31 July 2026 | Cantor Fitzgerald | Maintains | Overweight | $750 → $795 |
| 31 July 2026 | Morgan Stanley | Maintains | Equal-Weight | $730 → $758 |
| 31 July 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 31 July 2026 | RBC Capital | Maintains | Sector Perform | $696 → $737 |
| 31 July 2026 | RBC Capital | Maintains | Sector Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. REGN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Regeneron Pharmaceuticals, Inc. returned +31.8% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 40% of US stocks
Cheaper than 24% of US stocks
Cheaper than 38% of US stocks
Cheaper than 24% of US stocks
Higher than 65% of US stocks
Higher than 29% of US stocks
Higher than 95% of US stocks
Higher than 88% of US stocks
Higher than 87% of US stocks
Higher than 72% of US stocks
Higher than 83% of US stocks
Higher than 66% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Regeneron Pharmaceuticals, Inc. has a market value of $76.4B and an enterprise value of $68.5B.
Revenue in the twelve months to 30 June 2026: $15.5B. The latest quarter grew 16.7% year on year.
Net income over the same four quarters: $4.3B, a 27.9% net margin.
Diluted earnings per share, trailing twelve months: $40.46.
Free cash flow in the twelve months to 30 June 2026: $3.6B, after $920.9M of capital spending.
Regeneron Pharmaceuticals, Inc. spent $3.9B on share buybacks and $378.5M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 18.4×; forward P/E: 12.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.51%, paying out 9% of earnings.
Regeneron Pharmaceuticals, Inc. employs 15,410 people — $1.0M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Regeneron Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Goldman Sachs lead U.S. biotech analyst Salveen Richter discussed biotech innovations in China on CNBC’s “Closing Bell Overtime.” The headline says large biopharma companies are currently looking at assets in China.
Why it matters — The discussion concerns China biotech assets and large biopharma companies, a topic relevant to REGN watchers following the sector.
Regeneron highlighted late-breaking Phase 3 C-POST data at ESMO 2026, reporting longer-term survival outcomes for adjuvant Libtayo (cemiplimab) in high-risk cutaneous squamous cell carcinoma after surgery and radiation.
Why it matters — The update concerns longer-term outcomes for a Regeneron cancer treatment in a high-risk patient group.
Regeneron presented clinical trial results for two investigational therapies, one targeting recurrent ovarian cancer and another focused on preventing muscle loss during weight management. The data was shared on Thursday as part of the company's ongoing research efforts.
Why it matters — The trial data highlights progress in Regeneron's pipeline for two therapeutic areas—oncology and muscle preservation—that could expand its future product offerings.
Sanofi and Regeneron are expanding their long-standing immunology alliance to include four new antibodies targeting type II inflammation. The deal involves potentially billions of dollars in payments.
Why it matters — This expansion deepens Regeneron's partnership with Sanofi and adds new pipeline candidates in the inflammation space, potentially broadening the company's immunology portfolio.
Regeneron Pharmaceuticals discussed its expanded collaboration on next-generation long-acting immunology antibodies in a transcript featured by Seeking Alpha. The discussion centers on the company's ongoing research partnership in this therapeutic area.
Why it matters — Regeneron watchers would care because the expanded collaboration signals continued development activity in the company's immunology antibody pipeline.
The 27 Wall Street analysts covering Regeneron Pharmaceuticals, Inc. have a median 12-month price target of $857, with estimates ranging from $730 to $1,030. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 27 analysts covering Regeneron Pharmaceuticals, Inc., 18 rate it a Buy, 8 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Regeneron Pharmaceuticals, Inc. 93 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Regeneron Pharmaceuticals, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).
No one can know that. What the data says: the median 12-month target from 27 analysts implies +15.9% from the last close, and Ticker Nerd's factor model ranks Regeneron Pharmaceuticals, Inc. 93 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Regeneron Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for REGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $730 to $1,030 over the next 12 months.
Regeneron Pharmaceuticals, Inc. returned +31.8% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases.
The most recent item we track (CNBC Television, 6 Oct 2026): "Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter". Goldman Sachs lead U.S. biotech analyst Salveen Richter discussed biotech innovations in China on CNBC’s “Closing Bell Overtime.” The headline says large biopharma companies are currently looking at assets in China.
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and metabolic disease, infectious disease, hematology, and rare disorders. The company is known for combining laboratory research, clinical development, and in-house manufacturing to advance biologic therapies and antibody-based medicines. Regeneron also works on product candidates across multiple therapeutic areas, supporting a broad drug pipeline alongside its marketed medicines. Regeneron Pharmaceuticals, Inc. plays an important role in the healthcare market through its focus on specialty therapies designed for complex and often chronic medical conditions.
CEO Dr. Leonard S. Schleifer M.D., Ph.D. · 15,410 employees · United States · https://www.regeneron.com
